| 中文名称 |
Eliapixant
|
| 英文名称 |
Eliapixant
|
| 英文别名 |
Eliapixant;9GH7E6347B;Eliapixant [INN];Eliapixant [USAN];BDBM319844;US10174016, Example 11;WHO 11269;BAY 1817080;3-(5-methyl-1,3-thiazol-2-yl)-5-[(3R)-oxolan-3-yl]oxy-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide;3-(5-Methyl-1,3-thiazol-2-yl)-5-[(3R)-tetrahydrofuran-3-yloxy]-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;GTPL11969;BAY1817080
|
| Cas No. |
1948229-21-7
|
| 分子式 |
C22H21F3N4O3S
|
| 分子量 |
478.49
|
| 包装储存 |
Powder -20°C 3 years;4°C 2 years
|
| 详情描述 |
Eliapixant (BAY 1817080) 是一种有效和选择性的 P2X3 受体拮抗剂,IC50 值为 8 nM。Eliapixant 可用于难治性慢性咳嗽的研究。
|
| 产品详情 |
Eliapixant (BAY 1817080) 是一种有效和选择性的 P2X3 受体拮抗剂,IC50 值为 8 nM。Eliapixant 可用于难治性慢性咳嗽的研究。
|
| 生物活性 |
Eliapixant (BAY 1817080) is a potent and selective antagonist of P2X3 receptor, with an IC 50 of 8 nM. Eliapixant can be used for the research of refractory chronic cough.
|
| 性状 |
Solid
|
| IC50 & Target[1][2] |
IC50: 8 nM (P2X3 receptor)
|
| 体内研究(In Vivo) |
Eliapixant can be used for the research of coughs and diabetes complications. has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Powder -20°C 3 years;4°C 2 years
|
| ClinicalTrial |
|
| 参考文献 |
[1]. Spinaci A, et, al. P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications. Front Pharmacol. 2021 Apr 13;12:653561.[2]. Morice A, et, al. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240.
|
| 溶解度数据 |
In Vitro: DMSO : 33.33 mg/mL (69.66 mM; ultrasonic and warming and heat to 60°C)配制储备液
|
[1]. Spinaci A, et, al. P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications. Front Pharmacol. 2021 Apr 13;12:653561.[2]. Morice A, et, al. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240.
1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。
2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。